• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ACADIA Pharmaceuticals (ACAD) Looks Undervalued As Pipeline Momentum Keeps The Bull Case Alive

    Simply Wall St·09/16/2026 00:31:23
    Listen to the news

    ACADIA Pharmaceuticals (ACAD) has drawn attention after recent trading left the share price at US$26.76. The move came alongside mixed short-term returns and stronger performance over the past year and the past 3 months.

    Recent trading has taken some heat out of ACADIA Pharmaceuticals in the very near term, with the 1-day and 1-month share price returns both declining. However, the 90-day share price return of 23.89% and 1-year total shareholder return of 11.69% suggest momentum has been building rather than fading.

    Scan beyond ACADIA Pharmaceuticals and review other biopharma names showing strong momentum and fundamentals with our handpicked list of solid balance sheet and fundamentals (22 results)

    The recent pullback in ACADIA Pharmaceuticals after a strong multi month run raises a simple question: Are you seeing business fundamentals catching up, or sentiment cooling ahead of where the valuation sits today?

    Most Popular Narrative: 20% Undervalued

    At a last close of $26.76 versus a narrative fair value of $33.25, ACADIA Pharmaceuticals is framed as undervalued, with that gap anchored to expectations around its CNS pipeline and expanding rare disease portfolio.

    ACADIA's pipeline momentum, with 9 disclosed programs and multiple late-stage clinical readouts expected by 2027, positions the company to significantly diversify its revenue streams, reducing risk from single-product dependence and providing potential for margin expansion as new products are launched.

    See why 56 investors see ACADIA Pharmaceuticals as 20% undervalued.

    Result: Fair Value of $33.25 (UNDERVALUED)

    Still, the story around ACADIA Pharmaceuticals can change quickly if remlifanserin Phase 2 data underwhelm or if heavier reliance on NUPLAZID starts to worry investors.

    Find out about the key risks to this ACADIA Pharmaceuticals narrative.

    Next Steps

    If that mix of optimism and concern around ACADIA Pharmaceuticals feels familiar, then move quickly, review the data, and weigh both the 1 or more rewards and the 1 or more risks through the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond ACADIA Pharmaceuticals?

    If ACADIA Pharmaceuticals is already on your radar, do not stop there. Broadening your watchlist with other focused ideas can sharpen your decision making and help you spot opportunities earlier.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.